8 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.
Antitrust action referencing the '554 patent as an Orange Book-listed Revlimid patent; the '554 was not asserted as a claim in suit.
Clayton Act antitrust action referencing the '554 patent as an Orange Book-listed Revlimid patent; not asserted.
Antitrust action referencing the '554 patent as an Orange Book-listed Revlimid patent; not asserted.
Antitrust / assignment claims action referencing the '554 patent as an Orange Book-listed Revlimid patent; not asserted.
Antitrust class action referencing the '554 patent as an Orange Book-listed Revlimid patent; not asserted.
DrugPatentWatch reported the '554 among case patents, but because the '554 expired July 24, 2016, the narrative regards its appearance as a portfolio/background reference rather than an asserted patent; not confirmed as asserted.